Citi Pharma (KAR:CPHL) EV-to-EBIT: (As of Sep. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
5 GF Score
Price ₨71.08
! 1 Warning Sign
View Full Analysis

What is Citi Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Citi Pharma's Enterprise Value is ₨16,239.02 Mil. Citi Pharma does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Citi Pharma's EV-to-EBIT at this moment.

The historical rank and industry rank for Citi Pharma's EV-to-EBIT or its related term are showing as below:

KAR:CPHL's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 16.13
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Citi Pharma's Enterprise Value for the quarter that ended in . 20 was ₨0.00 Mil. Citi Pharma does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Citi Pharma's Earnings Yield (Joel Greenblatt) % at this moment.

Citi Pharma  (KAR:CPHL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Citi Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: . 20 ) =EBIT / Enterprise Value (Q: . 20 )
=/
= %

Citi Pharma EV-to-EBIT Related Terms

Citi Pharma EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Citi Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma EV-to-EBIT Chart

Citi Pharma Annual Data
Trend
EV-to-EBIT

Citi Pharma Semi-Annual Data
EV-to-EBIT

KAR:CPHL vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citi Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citi Pharma EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citi Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Citi Pharma's EV-to-EBIT falls into.


KAR:CPHL
5GF Score
Citi Pharma Ltd KAR:CPHL
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citi Pharma EV-to-EBIT Calculation

Citi Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=16239.022/
=

Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
5GF Score

Get the complete analysis for KAR:CPHL

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨71.08
Price